Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C

Robert J. Fontana, Ziad Kronfol, Karen L. Lindsay, Linas A. Bieliauskas, Latha Padmanabhan, Carla Back-Madruga, Anna S F Lok, Anne M. Stoddard

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

OBJECTIVE: Depression is a frequent side effect of interferon therapy in patients with chronic hepatitis C (CHC). The aim of this study was to identify baseline and on-treatment predictors of depression in CHC patients receiving peginterferon and ribavirin. METHODS: In total, 201 prior nonresponders with advanced fibrosis were treated with peginterferon alfa-2a and ribavirin for 24 wk in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial. Of these, 74 continued on antiviral therapy through week 48. Mood states were assessed with the Beck Depression Inventory II and the Composite International Diagnostic Interview. Plasma cortisol and whole blood serotonin levels were measured in 101 subjects at weeks 0, 4, 24, 48, and 72. RESULTS: The incidence of interferon-induced depression was 23% and 42% at weeks 24 and 48, respectively. Although 22% of patients had baseline depression, the absence of a week 20 virological response was the only independent predictor of interferon-induced depression at week 24 (P = 0.0009). Plasma cortisol levels did not change during treatment nor correlate with depression. In contrast, whole blood serotonin/platelet levels significantly decreased during treatment, but did not correlate with interferon-induced depression through week 24 (P = 0.35), nor through week 48 (P = 0.51). CONCLUSION: Depression during peginterferon and ribavirin therapy was associated with a lower antiviral response. The significant reduction in whole blood serotonin levels over time suggest that further studies of the serotonergic pathway are warranted to identify the mediators of interferon-induced depression.

Original languageEnglish
Pages (from-to)2766-2775
Number of pages10
JournalAmerican Journal of Gastroenterology
Volume103
Issue number11
DOIs
Publication statusPublished - Nov 2008
Externally publishedYes

Fingerprint

Ribavirin
Chronic Hepatitis C
Biomarkers
Depression
Interferons
Antiviral Agents
Therapeutics
Serotonin
Hydrocortisone
Fibrosis
Hepatitis C
Blood Platelets
Interviews
Equipment and Supplies

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Fontana, R. J., Kronfol, Z., Lindsay, K. L., Bieliauskas, L. A., Padmanabhan, L., Back-Madruga, C., ... Stoddard, A. M. (2008). Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C. American Journal of Gastroenterology, 103(11), 2766-2775. https://doi.org/10.1111/j.1572-0241.2008.02106.x

Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C. / Fontana, Robert J.; Kronfol, Ziad; Lindsay, Karen L.; Bieliauskas, Linas A.; Padmanabhan, Latha; Back-Madruga, Carla; Lok, Anna S F; Stoddard, Anne M.

In: American Journal of Gastroenterology, Vol. 103, No. 11, 11.2008, p. 2766-2775.

Research output: Contribution to journalArticle

Fontana, RJ, Kronfol, Z, Lindsay, KL, Bieliauskas, LA, Padmanabhan, L, Back-Madruga, C, Lok, ASF & Stoddard, AM 2008, 'Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C', American Journal of Gastroenterology, vol. 103, no. 11, pp. 2766-2775. https://doi.org/10.1111/j.1572-0241.2008.02106.x
Fontana, Robert J. ; Kronfol, Ziad ; Lindsay, Karen L. ; Bieliauskas, Linas A. ; Padmanabhan, Latha ; Back-Madruga, Carla ; Lok, Anna S F ; Stoddard, Anne M. / Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C. In: American Journal of Gastroenterology. 2008 ; Vol. 103, No. 11. pp. 2766-2775.
@article{5fefa65d2a8f47a3a7d44df9242eaa8f,
title = "Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C",
abstract = "OBJECTIVE: Depression is a frequent side effect of interferon therapy in patients with chronic hepatitis C (CHC). The aim of this study was to identify baseline and on-treatment predictors of depression in CHC patients receiving peginterferon and ribavirin. METHODS: In total, 201 prior nonresponders with advanced fibrosis were treated with peginterferon alfa-2a and ribavirin for 24 wk in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial. Of these, 74 continued on antiviral therapy through week 48. Mood states were assessed with the Beck Depression Inventory II and the Composite International Diagnostic Interview. Plasma cortisol and whole blood serotonin levels were measured in 101 subjects at weeks 0, 4, 24, 48, and 72. RESULTS: The incidence of interferon-induced depression was 23{\%} and 42{\%} at weeks 24 and 48, respectively. Although 22{\%} of patients had baseline depression, the absence of a week 20 virological response was the only independent predictor of interferon-induced depression at week 24 (P = 0.0009). Plasma cortisol levels did not change during treatment nor correlate with depression. In contrast, whole blood serotonin/platelet levels significantly decreased during treatment, but did not correlate with interferon-induced depression through week 24 (P = 0.35), nor through week 48 (P = 0.51). CONCLUSION: Depression during peginterferon and ribavirin therapy was associated with a lower antiviral response. The significant reduction in whole blood serotonin levels over time suggest that further studies of the serotonergic pathway are warranted to identify the mediators of interferon-induced depression.",
author = "Fontana, {Robert J.} and Ziad Kronfol and Lindsay, {Karen L.} and Bieliauskas, {Linas A.} and Latha Padmanabhan and Carla Back-Madruga and Lok, {Anna S F} and Stoddard, {Anne M.}",
year = "2008",
month = "11",
doi = "10.1111/j.1572-0241.2008.02106.x",
language = "English",
volume = "103",
pages = "2766--2775",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C

AU - Fontana, Robert J.

AU - Kronfol, Ziad

AU - Lindsay, Karen L.

AU - Bieliauskas, Linas A.

AU - Padmanabhan, Latha

AU - Back-Madruga, Carla

AU - Lok, Anna S F

AU - Stoddard, Anne M.

PY - 2008/11

Y1 - 2008/11

N2 - OBJECTIVE: Depression is a frequent side effect of interferon therapy in patients with chronic hepatitis C (CHC). The aim of this study was to identify baseline and on-treatment predictors of depression in CHC patients receiving peginterferon and ribavirin. METHODS: In total, 201 prior nonresponders with advanced fibrosis were treated with peginterferon alfa-2a and ribavirin for 24 wk in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial. Of these, 74 continued on antiviral therapy through week 48. Mood states were assessed with the Beck Depression Inventory II and the Composite International Diagnostic Interview. Plasma cortisol and whole blood serotonin levels were measured in 101 subjects at weeks 0, 4, 24, 48, and 72. RESULTS: The incidence of interferon-induced depression was 23% and 42% at weeks 24 and 48, respectively. Although 22% of patients had baseline depression, the absence of a week 20 virological response was the only independent predictor of interferon-induced depression at week 24 (P = 0.0009). Plasma cortisol levels did not change during treatment nor correlate with depression. In contrast, whole blood serotonin/platelet levels significantly decreased during treatment, but did not correlate with interferon-induced depression through week 24 (P = 0.35), nor through week 48 (P = 0.51). CONCLUSION: Depression during peginterferon and ribavirin therapy was associated with a lower antiviral response. The significant reduction in whole blood serotonin levels over time suggest that further studies of the serotonergic pathway are warranted to identify the mediators of interferon-induced depression.

AB - OBJECTIVE: Depression is a frequent side effect of interferon therapy in patients with chronic hepatitis C (CHC). The aim of this study was to identify baseline and on-treatment predictors of depression in CHC patients receiving peginterferon and ribavirin. METHODS: In total, 201 prior nonresponders with advanced fibrosis were treated with peginterferon alfa-2a and ribavirin for 24 wk in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial. Of these, 74 continued on antiviral therapy through week 48. Mood states were assessed with the Beck Depression Inventory II and the Composite International Diagnostic Interview. Plasma cortisol and whole blood serotonin levels were measured in 101 subjects at weeks 0, 4, 24, 48, and 72. RESULTS: The incidence of interferon-induced depression was 23% and 42% at weeks 24 and 48, respectively. Although 22% of patients had baseline depression, the absence of a week 20 virological response was the only independent predictor of interferon-induced depression at week 24 (P = 0.0009). Plasma cortisol levels did not change during treatment nor correlate with depression. In contrast, whole blood serotonin/platelet levels significantly decreased during treatment, but did not correlate with interferon-induced depression through week 24 (P = 0.35), nor through week 48 (P = 0.51). CONCLUSION: Depression during peginterferon and ribavirin therapy was associated with a lower antiviral response. The significant reduction in whole blood serotonin levels over time suggest that further studies of the serotonergic pathway are warranted to identify the mediators of interferon-induced depression.

UR - http://www.scopus.com/inward/record.url?scp=55349109617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55349109617&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2008.02106.x

DO - 10.1111/j.1572-0241.2008.02106.x

M3 - Article

C2 - 18721241

AN - SCOPUS:55349109617

VL - 103

SP - 2766

EP - 2775

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 11

ER -